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IMPACT OF STORAGE CONDITIONS ON MARROW AND PERIPHERAL
BLOOD STEM CELL PRODUCTS STORED OVER 72 HOURS
Kao, G.1, Kim, H.1, Gatzo, L.1, Madison, H.1, Daley, H.1,
Perzepiorka, D.2, Burger, S.3, Kelley, L.4, Vierra-Green, C.5,
Flesch, S.5, Spellman, S.5, Miller, J.5, Confer, D.5. 1Dana Farber Cancer
Institute, Boston, MA; 2University of Tennessee Health Science Center,
Memphis, TN; 3Advanced Cell and Gene Therapy, LLC, Chapel Hill,
NC; 4University of Utah, Salt Lake City, UT; 5NationalMarrowDonor
Program, Minneapolis, MN.
Hematopoietic stem cell (HSC) transplants from unrelated do-
nors are routinely used to treat patients with hematologicmalignan-
cies. HSC products are usually collected off site and require
transport to the transplantation centers. The impact of transport
conditions on HSC graft composition during short-term storage
have not been well described. This study evaluated the short-term
handling and storage conditions for marrow and PBSC products.
The study examined five bone marrow (BM) and four G-CSF mo-
bilized peripheral blood stem cell (PBSC) products from healthy
volunteers. Products were stored at 4C or 20C (RT) for up to
72 hrs. Product samples were evaluated at 0,24,48 and 72 hours
for WBC, viability, proliferative potential (CFC assay), CD341
cells, monocytes (CD141) and lymphocyte subsets
(CD31,4,8,52,56,20) during storage. Descriptive statistics and
multivariate repeated measures analysis were performed for each
of the variables and product. Percent cell viability, CD341/ml and
stem cell content CFU-GM/106 at t5 0 through 72 hrs are summa-
rized in table 1. Cell viability, stem cell, monocytes and lymphocyte
(except for CD81 and CD201) content for PBSC products de-
creased during 72 hrs regardless of storage temperature (p 5
0.0001). The rate of degradation was worse in products stored at
RT (p# 0.001). For BM products; WBC, cell viability, CFU-
GM, and CD41 cell content decreased over 72 hrs with more
significant decreases in WBC and CFU for products stored at
RT. Unlike PBSC, BM products stored at RT did not have signif-
icantly lower HSC content or viability than BM products stored at
4oC. The number of viable CD341/ul was not affected by storage
condition over time for BM products, but the quality of HSC as
measured by CFU significantly deteriorated after 72 hrs (p 5
0.0001). The HSC quality as measured by changes in product white
blood cell count, viable CD341 cells, cell viability, CFU colonies,
monocytes and lymphocyte subsets during storage and betweenChanges in HSC Product Characteristics Over Time
t 5 0 t 5 24 t 5 48 t 5 72
Total 7 AADViability % *
PBSC
4C 94.2 91.9 85.8 72.1
20C 94.2 77.1 46.6 39.3
BM
4C 97.9 94.3 99.4 96.5
20C 97.9 91.8 93.1 93.8
CD341/ml % *
PBSC
4C 100.0 99.8 98.1 83.2
20C 100.0 71.4 19.0 4.6
BM
4C 100.0 110.6 74.1 77.6
20C 100.0 154.2 94.3 105.6
CFU-GM/106 % *
PBSC
4C 100.0 152.7 162.4 38.2
20C 100.0 61.8 9.7 0.0
BM
4C 100.0 87.0 32.6 26.1
20C 100.0 43.5 32.6 30.4
*Base line percentage at t 5 0 hrs.temperatures worsened over time regardless of storage condition.
The primary objective of the study was to generate data to precisely
define optimal and acceptable methods for handling of hematopoi-
etic stem cells prior to infusion. Therefore, refrigerated storage of
PBSC and BM products appears to optimize the quality and quan-
tity of the product. This is particularly relevant for PBSC products
that may require multiple days for collection and/or transport.252
MOBILIZATION OF MURINE HSCs WITH AMD15057, A SMALL MOLE-
CULE INHIBITOR OF CD49d (VLA4)
Ramirez, P.A., Rettig, M., Holt, M., Ritchey, J., DiPersio, J.F. Wash-
ington University, St. Louis, MO.
Background: Developing hematopoietic stem cells (HSC) are
largely confined to the bone marrow (BM) microenvironment.
AMD3100 is a bicyclam molecule that potently, selectively, and re-
versibly antagonizes the binding of SDF-1 to CXCR4, and is the
most promising mobilizing agent currently in clinical development.
Significant data also support the role of VCAM1/VLA-4 axis in
HSC homing and mobilization. In this study, we compared the ki-
netics and efficacy of HSC mobilization by AMD15057, a small
molecule inhibitor of VLA-4, to AMD3100 and GCSF.Methods:
To evaluate the mobilization of HSC progenitors, 8 week old 129/
B6 F1 mice (n 5 6 per group, 3 experiments) were left untreated
(unmobilized) or treated with AMD15057 (1 mg/kg iv),
AMD3100 (5 mg/kg sc), G-CSF (250 mg/kg/day  5 days) or the
combination of AMD15057 and AMD3100. Total WBC and
CFU-GM were determined at different time points for each mobi-
lization regimen. For long-term competitive repopulation cell as-
says (LTRC), PBMCs from 3 CD45.21 unmobilized or mobilized
mice (700 uL PB each) were pooled, mixed with a fixed number
of 5  105 CD45.11 BM mononuclear cells (MNC) (3:1 ratio)
and injected into lethally irradiated CD45.11/CD45.21 recipient
mice. Chimerism was evaluated 18, 30, and 60 days after transplan-
tation by flow cytometry. Results: A single iv injection of
AMD15057 resulted in maximummobilization of CFU-GMwithin
1 h compared to 3 h after AMD3100. Dramatic synergism of CFU-
GM mobilization (120 fold over baseline) was seen when
AMD15057 was combined with AMD3100. Furthermore, the com-
bination of AMD15057 plus AMD3100 induced essentially equal
mobilization of long term marrow competitive repopulating
HSCs compared to GCSF treated donors (Table 1). Overall sur-
vival at 60 days after transplantation was 100% for all cohorts, ex-
cept for the unmobilized PB group (80% survival). Conclusions:
Rapid mobilization of CFU-GM cells can be induced by
AMD15057. AMD15057 synergized with AMD3100 to mobilize
long term marrow repopulating HSCs. These results show that
the VCAM1/VLA-4 axis is involved in HSC and progenitor cells
trafficking and retention in the bone marrow microenvironment.
Table 1. Percentage of CD45.2 donor cells in heterozygous recipients
Unmobilized AMD150571PB AMD15057 AMD3100 AMD3100 G-CSFDay 1 18 13 25 39 60 71Day 1 30 11 36 46 64 78Day 1 60 14 40 50 67 82253
DIMINISHED BIOLOGICAL POTENCY OF BM-DERIVED CD1331 CELLS
OBTAINED FROM PATIENTS WITH CORONARY ARTERY DISEASE IN
IN VITRO AND IN VIVO STUDIES
Greco, N.J., Finney, M., Joseph, M., Hammond, L.R., Forester, M.,
Bhakta, S., Goldberg, J., Scheid, P., Victor, A., Pompili, V.J.,
Laughlin, M.J. Case Western Reserve University, Cleveland, OH.
Whether significant differences in biological potency of
CD1331 stem cells exist between those from patients with stable
coronary ischemia compared to those from healthy controls or
94 Poster Session Ifrom umbilical cord blood (CB) is unknown.We performed in vitro
and in vivo studies comparing bone marrow (BM)-derived CD1331
cells from chronic coronary artery patients enrolled in the Safety
And Efficacy Of Autologous Intracoronary Stem Cell Injections
In Total Coronary Artery Occlusions (SEACOAST). Patient- and
control-derived blood cells mononuclear cells (MNC) from periph-
eral blood (PB) and BM were tested for endothelial cell colony for-
mation (CFU-EC), and tested functionally by in vitromigration and
the ability to augment blood flow in a mouse hindlimb ischemia
model. Patient-derived BM CD1331 cells, isolated with the Clini-
MACS device (84 6 7% purity and 76 6 7% viability (7–7AAD),
contained non-CD1331 cells following selection: \ 5% CD3,
CD3neg/CD56, CD19 (immature/mature), CD14, or CD71 cells,
5% CD611 cells, and 8% CD131 SSChigh cells. BM and PB-de-
rived MNC from patients produced less colonies compared to
healthy controls and CB: CB, 35.8 6 41.7, control PB, 79.6 6 49;
control BM, 24.8 6 13.7; patient PB, 6.9 6 9.3 and BM, 0.86 6
0.83. Transmigration of selected CD1331 cells to the stromal
cell-derived factor-1 (SDF-1) chemokine was performed. Transmi-
gration of control and patient-derived CD1331 cells in response to
200 ng/ml SDF-1 was 64.5 6 23.1% and 9.3 6 3.8%. Control or
patient-derived cells or media was injected (intracardiac) into
NOD/SCID mice after femoral artery ligation. Doppler flow mea-
surements comparing ischemic/healthy limb perfusion ratios at 28
days were higher in mice receiving control CD1331 cells (0.51 6
0.06) compared to those receiving media control (0.37 6 0.03, p
\ 0.05). No improvement of receiving patient-derived BM
CD1331 cells (0.46 6 0.04) or PB MNC (0.37 6 0.08) was ob-
served (p5 0.07, p5 0.94, respectively). Diminished biological po-
tency of chronic ischemic patient-derived cells was observed in in
vitro and in vivo studies when compared to cord blood and healthy
control-derived cells.254
AMD3100 MOBILIZES A MORE PRIMITIVE HEMATOPOIETIC PROGENI-
TOR SUBSET FROM HUMAN MARROW
Wagner, W.1,2, Fru¨hauf, S.1, Callandra, G.3, Ho, A.D.1. 1University of
Heidelberg, Heidelberg, Germany; 2University of Heidelberg, Germany;
3Genzyme, Boston, Germany.
Our group demonstrated the significance of specific adhesion
molecules and of junction formation between human hematopoietic
progenitor cells (HPC) and human mesenchymal stromal cells
(MSC) in maintaining stemness. For example, CXCR4/SDF-1a as
well as b1-integrins were shown to be major mediators of stem
cell homing and adhesion to the niche. AMD3100, a novel
CXCR4 antagonist, inhibits efficiently the binding of CXCR4 to
SDF1a and has been shown to induce a rapid release of HPC
from the bone marrow to peripheral blood.
We have monitored migration and cell-cell adhesion of HPC to-
wards MSC under the influence of SDF-1a, AMD3100 and the ap-
propriate controls. Simultaneously we participated in amulti-center
trial sponsored by Anormed (Vancouver, Canada, subsequently
Genzyme, Boston) in patients who were poor mobilizers. Patients
with multiple myeloma and non-Hodgkin-lymphoma were treated
with AMD3100 administered 12 hours before apheresis and follow-
ing 4 days of granulocyte colony-stimulating factor (G-CSF),. This
offered the opportunity to measure the numbers, the phenotypes
and function of the CD341 cells mobilized by AMD3100 1 G-
CSF versus those by G-CSF alone in the same subjects.
The primitive subsets (CD341/CD38-) were significantly more
adherent to MSC than the committed HPC (CD341/CD381).
Functionally LTC-IC were found exclusively among the HPC ad-
herent to MSC. There was a significant reduction in adhesion of
HPC to MSC upon in vitro treatment with AMD3100 (32% 6
11%; P5 7 10–5) or with SDF-1a (55%6 13%; P5 .014), versus
controls (74%6 10%). Analysis ofHPCmobilized by AMD31001
G-CSF in the patients (n 5 7) indicated that HPC are completely
different from those mobilized with G-CSF. The most significant
findings were (1) an overall increase in the concentration of
CD341 cells after administration of AMD3100 (2.8 fold with
a range from 1.1X to 6.9X), and (2) an increase in the primitive sub-
set CD341/CD38- cells versus stimulation with G-CSF alone. Themedian increase in CD341/CD38- was 3.6 fold with a range of
1.3X to 5.7X. Parallel to this increase, functional assay also indi-
cated that the CD341 cells mobilized by G-CSF1AMD3100
were more potent, LTC-IC being 1.4 fold with a range from 1.1X
to 2.6X as compared to that after G-CSF alone. Thus a precise un-
derstanding of the mechanisms behind homing and adhesion of
HPC to the cellular niche has led to the development of a novel
agent for the efficient mobilization of more potent HPC.255
RESCUEMOBILIZATION OF HEMATOPOIETIC PROGENITOR CELLSWITH
AMD3100 1 G-CSF IS SUCCESSFUL IN PATIENTS WHO PREVIOUSLY
FAILED MOBILIZATION
Micallef, I.N.M.1, Ansell, S.M.1, Buadi, F.1, Dispenzieri, A.1,
Elliott, M.A.1, Gertz, M.A.1, Hayman, S.R.1, Hogan, W.J.1,
Inwards, D.J.1, Gastineau, D.A.1, Johnston, P.B.1, Kumar, S.1,
Lacy, M.Q.1, Porrata, L.F.1, Marzolf, M.1, Shaw, T.1, Winters, J.L.2,
Calandra, G.3, Litzow, M.R.1. 1Mayo Clinic, Rochester, MN; 2Mayo
Clinic, Rochester, MN; 3Genzyme Transplant, Cambridge, MA.
Background: The failure rate for hematopoietic progenitor cell
mobilization varies from 5% inMultipleMyeloma pts to 30% in pts
with non-Hodgkin lymphoma and Hodgkin lymphoma.Methods:
We report the results of a single center experience with AMD3100
(plerixafor)1G-CSF as a rescue progenitor cell mobilization in pa-
tients who had failed a prior mobilization. Mobilization failure was
defined as inability to collect$ 2 106 CD341 cells/kg or inability
to achieve a peripheral bloodCD341 cells/ml of$10 and not apher-
esed. Rescue mobilization consisted of G-CSF at 10 mcg/kg/day sq
on days 1–4 plus AMD3100 at 240 mcg/kg/day sq on the evening of
day 4 and continued until the goal of 5  106 CD341 cells/kg was
reached or a maximum of 7 aphereses. Apheresis began on day 5 re-
gardless of the peripheral bloodCD341 cells/ml.Results:Twenty-
nine pts participated in this compassionate use protocol. Demo-
graphics were 11 females and 18 males; 14 pts had NHL, 10 MM,
3 AL amyloidosis and 2 HD. The median age was 63 years (range
37–73). Prior mobilization was G-CSF alone in 25 pts, G-CSF 1
GM-CSF in 2 and chemotherapy 1 G-CSF in 2. Median time
from prior mobilization failure to AMD3100 rescue mobilization
was 0.7 months (range 0.4–33). The median peripheral blood
CD341 cells/ml value prior to AMD3100 was 4.8 (range 0–18.2)
and 12 hours post AMD3100 was 12.4 (range 2–49.5), a 2.7 fold in-
crease (range 0.5–7.4). The median number of CD341 cells har-
vested was 4.71  106 CD341 cells/kg (range 0.25–9.37). Seven
pts (24%) failed to achieve a minimum of $2  106 CD341
cells/kg. Twenty-two of 29 pts (76%) successfully collected at least
2 106 CD341 cells/kg and 12 (41%) collected$ 5 106 CD341
cells/kg. Median number of aphereses in the successful pts was 5
(range 2–7) and the median number of aphereses to reach 2  106
CD341 cells/kg was 2 (range 1–7). Twenty-five pts (86%) went
on to ASCT. This included 4 pts who collected # 2  106
CD341 cells/kg (1.01, 1.44, 1.5, and 1.98) and underwent bone
marrow harvest. One pt who successfully collected has not yet un-
dergone ASCT. All pts had successful engraftment; median time
to neutrophil engraftment (500/ml) was 13 days (range 11–18) and
median time to platelet engraftment (50,000/ml) was 22 days (range
16–231).Conclusion: The addition of AMD3100 to G-CSF effec-
tively mobilizes CD341 cells in themajority of pts, in whom a prior
mobilization with either growth factors or chemotherapy has failed
to mobilize sufficient cells for ASCT.256
POTENTIAL BIODOSIMETRY MARKERS OF RADIATION EXPOSURE
Upton, A., Kharbanda, S., Sande, J.E., Gage, J., Wang, D., Johnson,M.
University of Alabama, Birmingham, AL.
Background: According to a Joint Interagency Group directed
by the Department of Defense, radiological dose assessment is im-
perative to decrease morbidity and mortality following a radiologi-
cal event. Dose assessment requires the development of rapid,
